Dr. Judy S. Wang, MD

Dr. Wang practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Wang's NPI, 1053554717, was assigned on April 10, 2009. Dr. Wang graduated from Penn State College of Medicine in 2009. Dr. Wang holds Florida license ME123610.

Dr. Wang's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Wang's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Wang is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Wang to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wang is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Wang's licenses on file in 3 states: Florida, Maryland and Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, neutropenia and prostate cancer among the conditions Dr. Wang treats.

CMS data shows 4,384 Medicare services from Dr. Wang across 19 procedure codes in 2024, for 156 Medicare patients. Medicare paid $91,086 for them. Every service was in an office.

CMS counts 156 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 97 patients. 67% of them have cancer, and 54% have high blood pressure. Their average risk score is 3.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 69, with 58% women.

In 2024, Dr. Wang wrote 414 Medicare Part D claims for 81 patients. 92% of them were for generic drugs. CMS names the drug for 169 of them, across 9 drugs with 11 or more claims each, at $1,801 in total drug cost. In 2023, CMS named 202 claims across 12 drugs.

Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wang as offering telehealth.

Dmand AI links 25 papers to Dr. Wang, published from 2015 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Maximum Tolerated Dose, Antineoplastic Combined Chemotherapy Protocols and Antibodies, Monoclonal, Humanized. Dr. Wang has published most often in Invest New Drugs. Dr. Wang's most frequent co-authors are Gerald Steven Falchook, MD, Todd Michael Bauer, MD and Shubham Pant, MD.

Dmand AI links Dr. Wang to 27 clinical trials, 15 of them phase 1 studies. 6 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma. AstraZeneca sponsors the most, 6. Open Payments lists research payments to Dr. Wang that name 1 trial.

CMS Open Payments shows 699 general payments to Dr. Wang from 77 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 72% of the total. AstraZeneca Pharmaceuticals LP paid the most, $66,552. It also lists 1 research payment totaling $62,131 in 2018, naming 1 clinical trial.

Dr. Wang graduated from Penn State College of Medicine in 2009.

Dr. Wang is in network with 19 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.